['diabetes', 'diabetes mellitus, type 1']
['faster-acting insulin aspart', 'insulin aspart', 'insulin degludec']

        Inclusion Criteria: - Male or female, age greater than or equal to 18 years ( for Japan and
        Taiwan: age greater than or equal to 20 years) at the time of signing informed consent -
        Type 1 Diabetes Mellitus (based on clinical judgement and/or supported by laboratory
        analysis as per local guidelines) 12 months or more prior to screening - Currently treated
        with a basal-bolus insulin regimen for at least 12 months prior to screening (Visit 1) -
        Currently treated with a basal insulin analogue for at least 4 months prior to screening
        (Visit 1) - HbA1c 7.0-9.5% (53-80 mmol/mol) (both inclusive) as assessed by central
        laboratory - Body Mass Index less than or equal to 35.0 kg/m^2 Exclusion Criteria: - Within
        the past 180 days any of the following: myocardial infarction, stroke or hospitalization
        for unstable angina and/or transient ischemic attack - Subjects presently classified as
        being in New York Heart Association (NYHA) Class IV Currently planned coronary, carotid or
        peripheral artery revascularisation - Diabetic ketoacidosis requiring hospitalisation
        within the last 180 days prior to screening (Visit 1) - Treatment with any medication for
        the indication of diabetes or obesity other than stated in the inclusion criteria in a
        period of three months before screening (Visit 1)
      